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INTRODUCTION
The CDKN2A and TP53 tumor-suppressor genes are two of the most frequently inactivated genomic loci in human cancers (Sherr et al., 2005) . CDKN2A encodes two unrelated proteins, p14 ARF (p19 ARF in mice) and p16
INK4A
, both of which function as tumor suppressors (Quelle et al., 1995) . This unprecedented genomic organization leads to the sharing of exons 2 and 3 by ARF and p16, but due to distinct promoters and first exons, ARF is translated in an alternative reading frame, hence its name. p16 is a well-characterized cyclin-dependent kinase inhibitor, and functions to keep the retinoblastoma protein (Rb) in a hypophosphorylated state, effectively blocking entry into S phase of the cell cycle (Roussel, 1999) . ARF, in response to hyperproliferative and hypergrowth cues, induces p53 stabilization by binding to and sequestering the p53 E3 ubiquitin ligase MDM2 in the nucleolus (Saporita et al., 2007; Zindy et al., 1997) . Relief of the inhibitory effects of MDM2 allows p53 to activate transcriptional programs leading to cell-cycle arrest or apoptosis (Riley et al., 2008) . Thus, ARF and p53 are thought to function in a linear genetic pathway that functions to protect cells from inappropriate oncogenic signaling (Sherr, 2001) .
Since ARF's initial discovery, it has been observed that cells lacking p53 function contain elevated levels of ARF (Quelle et al., 1995; Stott et al., 1998; Zindy et al., 1998) . A mechanistic explanation for this phenomenon surfaced when it was recently shown that p53 is a potent transcriptional repressor of the CDKN2A promoter. Recruitment of histone deacetylases and Polycomb group proteins by p53 renders the locus inaccessible to transcription factors (Zeng et al., 2011) . Thus, in the context of p53 loss of function, ARF transcription is derepressed and protein levels become elevated. It is heavily debated whether these induced protein levels are functional.
Mounting evidence suggests ARF possesses important p53-independent tumor-suppressor functions, supported by the findings that TP53 and CDKN2A are frequently coinactivated in human cancers (Cancer Genome Atlas Research Network, 2012; O'Dell et al., 2012; Rozenblum et al., 1997; Sanchez-Cespedes et al., 1999; Saporita et al., 2007; Sherr, 2006) . Admittedly, it remains unclear which CDKN2A gene product, ARF or p16, is selected against in tumors. However, several groups have shown that p53-null cells are sensitive to exogenous overexpression of ARF, demonstrating that ARF can function independently of p53 to inhibit proliferation and suggesting a selective pressure might exist to selectively silence ARF in the absence of p53 (Sherr, 2006; Sherr et al., 2005; Weber et al., 2000) . Here, we show that acute p53 loss results in an induction of ARF protein expression and that this endogenous ARF accumulation functions to limit the proliferation and tumorigenicity of p53-deficient cells. Furthermore, we demonstrate that this elevated ARF expression inhibits a protumorigenic signaling cascade mediated by interferon b (IFN-b) secretion and activation of the STAT1 transcription factor. We propose that in the absence of both p53 and ARF, IFN signaling is undeterred and cellular transformation is enhanced, a finding that we substantiate in primary human breast cancers.
RESULTS

Acute p53 Loss Induces Functional ARF
It has long been assumed that the high levels of ARF found in p53-deficient cells are not tumor suppressive. To directly address this assumption, we utilized a conditional mouse model of p53 inactivation where exons 2-10 are flanked by loxP sites . Adenoviral (Ad) delivery of Cre-recombinase into p53 flox/flox mouse embryonic fibroblasts (MEFs) resulted in an accumulation of ARF mRNA and protein by 4 days postinfection, and levels continued to rise over time and passage ( Figures 1A and 1B) . These data are in agreement with previous findings that p53 directly binds to and is capable of repressing the ARF promoter (Zeng et al., 2011) . Importantly, a transcriptional target of p53, MDM2, was reduced following excision of p53 ( Figure 1A ).
These p53 D/D MEFs, hereafter referred to as dp53 cells (deleted for p53), proliferated faster than LacZ-infected controls, exhibited more rapid S phase entry, and formed numerous foci when plated at low density ( Figures 1C-1E ). Infection of dp53 MEFs with a short hairpin RNA (shRNA) specifically targeting ARF resulted in further enhancement of proliferation and foci formation ( Figures 1F-1H ), indicating that the proliferation of p53-deficient cells is constrained by endogenously induced ARF protein. Importantly, shRNA-mediated depletion of ARF did not reduce p16 levels, indicating the observed enhancement of proliferation was specifically due to ARF loss ( Figure S2A ).
Endogenous ARF Limits the Tumorigenicity of p53-Deficient Cells
To test the tumor-suppressive functions of ARF in the context of p53 loss, we overexpressed mutant H-Ras V12 in dp53 MEFs and then depleted ARF ( Figure 2A ). As seen in Figure 2 , Ras V12 -transformed dp53 MEFs (dp53R MEFs) were capable of forming colonies in soft agar ( Figure 2B , top left panel). However, depletion of ARF in the dp53R MEFs resulted in a tremendous increase in the size of soft agar colonies, indicating an increase in tumorigenic potential ( Figures 2B and 2C ). The dp53R-shARF MEFs also exhibited higher proliferative rates, bromodeoxyuridine (BrdU) incorporation rates, and increased foci formation compared to dp53R-shSCR cells, supporting our observed tumorigenic phenotype ( Figures 2D-2F ). To extend our findings in vivo, we injected the dp53R-shARF cells into the flanks of nude mice. We observed a striking enhancement in the growth kinetics of dp53R-shARF tumors relative to tumors formed with dp53R-shSCR cells (Figures 2G and 2H) . Taken together, these data demonstrate the endogenous ARF levels that accumulate following p53 loss function to limit tumorigenicity.
ARF Inhibits an Interferon-Sensitive Gene Signature Induced upon p53 Loss Having demonstrated that the induced levels of ARF in p53-deficient cells serve a tumor-suppressive function (Figure 2 ), we sought to understand which oncogenic processes ARF might be inhibiting to limit tumorigenicity. The previously ascribed p53-independent tumor-suppressive roles of ARF include regulating general or mRNA-specific translation (Apicelli et al., 2008; Kawagishi et al., 2010; Kuchenreuther and Weber, 2014; Sugimoto et al., 2003) , inhibition of transcription factors such as c-Myc (Qi et al., 2004) , and modulation of protein sumoylation (Kuo et al., 2008) . We analyzed these processes in our system and observed no significant differences between dp53R-shSCR and dp53R-shARF MEFs (data not shown).
Therefore, we took an unbiased approach to identify changes in global mRNA expression between dp53R-shSCR and dp53R-shARF MEFs. Comparative microarray analysis yielded numerous upregulated immune response genes in the dp53R-shARF cells, including Irf7, Oasl2, Ifit3, Usp18, Mx2, and Isg15 (Figures 3A and 3B) . Pathway analysis indicated that the gene signature was most strongly associated with the innate immune response or type I IFN response ( Figure 3B ). The interferon-sensitive gene (ISG) expression changes were validated by quantitative RT-PCR (qRT-PCR) ( Figure 3C ).
As an important control, we analyzed ISG expression in our cell lines following infection with the various viral constructs used in our experiments and compared to mRNA levels in ''mock''-infected cells (no virus). Retroviral infection with empty vector or Ras V12 did not induce ISGs, and lentiviral infection of Arf-null or wild-type MEFs with shSCR or shARF had no effect on ISG mRNA levels ( Figures S1A-S1C ). Furthermore, a comparison of three different low-passage (<passage 6) wild-type and Arf-null MEF lines showed no increase in ISG expression (Figure S1D) . The only genetic setting where ARF depletion induced ISGs was in the context of p53 deficiency ( Figure S1E ). Additional experiments were performed to assess the role of p16INK4a in ISG induction. As shown in Figure S2 , an shRNA targeting both ARF and p16 was unable to induce an additive effect on ISG expression ( Figures S2B and S2C) . Moreover, specific depletion of p16 in dp53R MEFs did not induce ISG expression ( Figures S2D and S2E) . Thus, ARF's inhibition of ISG expression is entirely dependent on a p53-deficient genetic setting, and p16 knockdown does not produce the same effects.
Given ARF's ability to inhibit ISG expression exclusively in the context of p53 deficiency, we hypothesized that loss of p53 might be the driving force behind upregulation of the ISGs and that the induction of ARF would then serve as a biological ''brake'' to suppress the response. To test this hypothesis, we analyzed ISG mRNA expression following infection of p53
flox/flox
MEFs with Ad-Cre or -LacZ control. As shown in Figure 3D , expression of ISG15 and OASL2 are induced at 4 and 6 days after p53 loss. Consistent with our hypothesis, 8 days after p53 loss, when ARF protein levels are maximally induced, we no longer observed a significant induction of the ISGs ( Figures 3D  and 3E ). The suppression of ISG15 and OASL2 expression 8 days after p53 loss was completely relieved when ARF-specific shRNA was introduced. Therefore, the negative feedback p53 imposes on ARF exists to allow ARF to respond to acute p53 loss by inhibiting an induction of ISGs.
Having demonstrated ARF and p53 cooperate to suppress expression of ISGs in vitro, we sought to establish the existence of this signaling pathway in vivo. We generated cohorts of BlgCre;p53 flox/flox ;Arf +/+ and Blg-Cre;p53 flox/flox ;Arf flox/flox mice to analyze the effects of losing p53 alone versus losing both Arf and p53. Activation of Cre-recombinase by the beta-lactoglobulin (Blg) promoter induces recombination of floxed alleles specifically in the mammary gland of lactating female mice 
IFN-b Is Necessary and Sufficient for Increased Tumorigenicity in dp53R-shARF MEFs
Our microarray data and pathway analysis indicated an activation of the type I IFN response, or more specifically, response to IFN-b. We analyzed IFN-b mRNA expression using qRT-PCR in our dp53R-shARF MEFs and consistently observed a 2-to 3-fold induction ( Figure 4A ). Additionally, this 3-fold induction of IFN-b mRNA resulted in a nearly 11-fold increase in IFN-b secretion in the media containing dp53R-shARF cells as measured by ELISA ( Figure 4B ). To determine the requirement of secreted IFN-b for cell proliferation, we knocked down IFN-b in dp53R-shARF cells. This resulted in a significant decrease in both IFN-b expression and phosphorylated STAT1 ( Figures 4C  and 4D ). Long-term proliferation was significantly impaired in cells with reduced IFN-b ( Figure 4E ), indicating a requirement for IFN-b production in dp53R-shARF cells.
Next, we sought to determine if enhanced production of IFN-b was sufficient to promote the aberrant proliferation of dp53R cells in the presence of high ARF levels. Using concentrations of recombinant IFN-b that matched the concentration range detected in the media of dp53R-shARF cells, we observed a significant increase in long-term proliferation of dp53R cells that was comparable to that seen in dp53R-shARF cells ( Figure 4G ). Markedly, recombinant IFN-b stimulated ISG15 expression to the same level seen in dp53R-shARF cells ( Figure 4F ). Therefore IFN-b production is sufficient to phenocopy the signaling pathway activation and proliferative gains seen with ARF knockdown in dp53R cells.
ARF Represses a Protumorigenic STAT1-ISG15 Signaling Cascade
Canonical IFN-b signaling occurs upon ligand binding to the membrane receptors IFNAR1/2. Upon ligand binding, a conformational change allows autophosphorylation of receptor-bound JAK1 and TYK2. The activation of these kinases leads to phosphorylation of STAT1 and STAT2 proteins, which enables them to enter the nucleus. Once inside the nucleus, the STAT1/ STAT2 heterodimer associates with IRF9 to form a complex known as interferon-stimulated gene factor 3 (ISGF3), which is fully capable of initiating transcription of genes containing interferon-stimulated response elements (ISREs) (Platanias, 2005) . Many of the genes in our ISG signature contain ISREs in their promoters (Sadler and Williams, 2008) , and it is well established that activation of the STAT1 transcription factor is required for upregulation of ISRE-containing genes (Ramana et al., 2000) . Therefore, we analyzed STAT1 status in dp53R-shARF cells and observed increases in the phosphorylation of both tyrosine 701 and serine 727 activation sites as well as an accumulation of total STAT1 levels ( Figure 5A ). Neither STAT3 activation nor increased expression of its upstream cytokine, interleukin-6, was observed in the same genetic context ( Figure S4 ). The increase in total STAT1 was due to an increase in mRNA levels, consistent with the observation that the STAT1 promoter contains an ISRE ( Figure 5B ) (Zimmerman et al., 2012) . To test whether STAT1-mediated signaling was required for the increased tumorigenicity in the dp53R-shARF MEFs, we used shRNAs to deplete STAT1. Reducing total STAT1 protein levels led to a concomitant decrease in phosphorylation in dp53R-shARF MEFs ( Figure 5C ). As shown in Figure 5D , mRNA expression of select ISGs was also reduced following STAT1 knockdown. Short and long-term proliferation of dp53R-shARF MEFs was inhibited and colony growth in soft agar was reduced (Figures 5E-5G) . Taken together, these data indicate that ARF protects p53-deficient cells from inappropriate STAT1 activation and, if left unchecked, signaling through STAT1 can lead to increased tumorigenicity. Interestingly, one of the IFN-responsive genes, Isg15, encodes a ubiquitin-like protein that is conjugated to lysine residues and has recently been shown to be required for the tumorigenicity of select breast cancer cell lines (Burks et al., 2014) . Increased ISG15 expression in dp53R-shARF MEFs is dependent upon STAT1 ( Figure 5D ), so we hypothesized ISG15 might represent one of the protumorigenic targets activated downstream of STAT1. Western blot analysis confirmed upregulation of both free and conjugated species of ISG15 in dp53R-shARF cells ( Figure 6A ). Using an shRNA specific to ISG15, we observed a significant reduction in soft agar growth, foci formation, and proliferation in the dp53R-shARF MEFs upon ISG15 knockdown ( Figures 6B-6E ), indicating that elevated ISG15 is required for the tumorigenesis of dp53R-shARF cells.
Analysis of TNBC Patient Samples and Cell Lines
We have demonstrated that ARF protein induced by p53 loss protects against the tumorigenic accumulation of an ISG signature in a mouse model system. To investigate whether this pattern of regulation was conserved in human cells, we focused on triple-negative breast cancer (TNBC) because over 80% of these patients harbor p53 mutations (Ellis and Perou, 2013) . We performed immunohistochemical analysis on an annotated breast cancer tissue array and scored the triple-negative cores (Table S1 ). Whereas elevated expression of ARF would be expected in the presence of p53 mutation, we observed that 11 of the 13 samples with p53 mutation exhibited low or no ARF staining, suggesting coinactivation of both ARF and p53. Further, 6 of 11 tissues with both ARF and p53 loss of function displayed intense staining of STAT1 and ISG15 ( Figures 7A  and 7B) .
Finally, we analyzed a panel of five TNBC cell lines. The HCC70 cell line, which displayed high ARF protein expression, was resistant to STAT1 depletion ( Figures 7C, 7D, and S5A) . The other four cell lines, which did not express ARF, were all extremely sensitive to STAT1 depletion, displaying signs of cytotoxicity ( Figures 7C, 7D , and S5B). The short hairpins targeting STAT1 did not reduce STAT3, a known promoter of breast cancer tumorigenesis (Marotta et al., 2011) (Figure S5C ), confirming the selective requirement of STAT1 activation in controlling the proliferation of these cells. Interestingly, the HCC70 cell line that was resistant to STAT1 depletion also expressed the highest level of ISG15 among the TNBC cell lines assayed ( Figure S5A ). We hypothesized that this cell line might have upregulated ISG15 independently of STAT1-mediated transcription. In agreement with this hypothesis, depletion of STAT1 in HCC70 cells did not reduce ISG15 levels ( Figure S6A ). Given our results in Figure 6 , which indicated ISG15 is one of the key protumorigenic effectors upon ARF depletion, we tested whether depleting ISG15 in HCC70 cells would inhibit their proliferation. Indeed, shRNA-mediated reduction of ISG15 significantly reduced HCC70 cell proliferation ( Figures S6B and  S6C ). Taken together, these data demonstrate that inhibition of type I IFN signaling components like STAT1 and ISG15 can inhibit proliferation of TNBC cell lines and also that other deregulated pathways in addition to ARF/p53 are likely capable of inducing ISG expression.
DISCUSSION
Our work has provided an answer to a long-standing question in cancer biology: What biological advantage does a normal cell gain by having the p53 tumor suppressor repress transcription of another tumor suppressor, ARF? We have shown that loss of p53 leads to a potent induction of ARF protein levels and that this large endogenous pool of ARF functions to limit proliferation and tumorigenicity in the face of oncogenic transformation.
To our surprise, depletion of ARF in p53-deficient cells led to an induction of ISGs through secretion of IFN-b and activation of the transcription factor STAT1. Our data further demonstrated collaboration of p53 and ARF in suppressing STAT1 signaling activation and subsequent ISG transcriptional activation both in vitro and in vivo. This cooperation was specific to p53 and ARF, because p16 was not shown to be important in suppressing ISG expression. Therefore, we propose that loss of p53 leads to two important events: induction of ISGs and the induction of ARF protein levels. Once ARF protein levels reach maximal expression, the transcription of ISGs is inhibited. In these cells, deletion or mutation of the Arf locus would predict an upregulation of the IFN gene signature and a subsequent tremendous growth advantage. Therefore, our results suggest a selective pressure does exist to coinactivate both ARF and p53, which indeed occurs in several cancer types (Cancer Genome Atlas Research Network, 2012; O'Dell et al., 2012; Rozenblum et al., 1997; Sanchez-Cespedes et al., 1999) .
Mechanistically, we do not yet understand how loss of p53 acts to induce expression of ISGs or how ARF functions to suppress the response. However, several recent publications are in support of our findings and provide potential mechanistic explanations. Cheon et al. showed that loss of p53 can induce unphosphorylated STAT1, which was shown to function in an unphosphorylated ISGF3 (U-ISGF3) complex to induce expression of select ISGs, providing resistance to DNA damaging agents (Cheon et al., 2013) . Many of these ISGs overlap with the ones in our gene expression profile. Intriguingly, they also demonstrated that low-level IFN-b, comparable to the levels used in our studies, was capable of inducing activity of this U-ISGF3 complex (Cheon et al., 2013) . A recent report has also suggested p53 is involved in suppressing the expression of dsRNA from noncoding portions of the mouse genome (Leonova et al., 2013 ). An increase in cellular dsRNA as a result of endogenous insults can activate a type I IFN response (Chiappinelli et al., 2012) . Future studies will be necessary to explore these possibilities. With regards to suppression of ISG expression by ARF, we have demonstrated that ARF and STAT1 can interact in dp53 MEFs, and we are currently working to understand the biological significance of this interaction (J.T.F., unpublished data).
While the activation of the type I IFN pathway is typically observed in the context of viral defense, numerous groups have found upregulation of this pathway in human cancers (Buess et al., 2007; Duarte et al., 2012; Perou et al., 1999; Zimmerman et al., 2012) . The importance of IFN signaling in human cancer is still a debated topic, but most commonly, activation of a type I IFN signature is thought to be tumor suppressive (Chan et al., 2012; Yu et al., 2009 ). In fact, type I IFN is an approved treatment for many diverse cancer types (Dunn et al., 2006) . Our work provides evidence for the direct involvement of IFN-b, STAT1, and a downstream ISG, ISG15, in promoting tumorigenicity. Each of these components was required for the enhanced tumorigenicity we observed in the dp53R-shARF MEFs. Moreover, in cells lacking p53, recombinant IFN-b alone was sufficient to stimulate proliferation.
Finally, we identified a subset of TNBC patients harboring coinactivation of ARF and p53 alongside overexpression of STAT1 and ISG15. Additionally, STAT1 depletion in a panel of p53 mutant TNBC cell lines showed that only cells lacking ARF expression were sensitive to the STAT1 shRNAs. Because existing mouse knockout models suggest that normal cells do not require the activity of STAT1 and ISG15 for viability (Durbin et al., 1996; Osiak et al., 2005) , targeted therapy of this pathway should be considered ideal for tumor reduction. Moreover, this IFN signaling axis need not be limited to TNBC, because numerous other cancers exhibit concomitant loss-of-function p53 and ARF.
The crosstalk between p53 and ARF has proven to be a multifaceted affair. ARF is induced in response to oncogenic signals Table S1. to activate p53; ARF is also induced by loss of p53 to suppress STAT1 signaling. Our findings support a model whereby induction of ARF following p53 loss acts to prevent aberrant IFN-b production and signaling to crucial downstream effectors. Thus, the functional links between p53 and ARF are far more imperative than anticipated. The complex p53-ARF network that we have identified provides tumor-suppressive redundancy where none was thought to exist in cells. We believe our study, combined with several recent reports, indicates a need to more carefully examine the functional importance of IFN signaling in cancer cells to ensure the use of IFN as a treatment option does not produce an undesirable outcome (Burks et al., 2014; Tsai et al., 2011; Zimmerman et al., 2012) . Moreover, our work suggests a subset of human cancer patients, those containing p53 and ARF mutations, might benefit from targeted inhibition of STAT1 or ISG15 activation. ) mice were obtained from the National Cancer Institute Mouse Repository and have been previously described ).
Cell Culture
Primary MEFs were isolated as previously described (Kamijo et al., 1997) . All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 2 mg/ml gentamicin. Recombinant IFN-b was obtained from PBL Interferon Source and used at the indicated concentrations.
Viral Production and Infections
Adenoviruses expressing b-galactosidase (Ad-LacZ) or Cre recombinase (AdCre) were purchased from the Gene Transfer Vector Core, University of Iowa. For adenoviral infections, 1 3 10 6 cells were plated in the presence of Ad-LacZ or Ad-Cre (MOI = 50) and incubated for 8 hr. For mutant Ras V12 overexpression, retrovirus was produced by transfecting 293T cells with either MSCV-HRAS V12 -IRES-GFP plasmid or MSCV-IRES-GFP control and the helper plasmid c-2. Virus-containing supernatants were harvested 48 hr posttransfection. Collected retrovirus was used to infect 1 3 10 6 MEFs in the presence of 10 mg/ml polybrene. For the production of lentiviral shRNAs, 293T cells were transfected using Lipofectamine 2000 (Invitrogen) with pCMV-VSV-G, pCMV-DR8.2, and pLKO.1-puro constructs. Viral supernatants were harvested 48 hr posttransfection. Cells were infected with lentivirus for 8-12 hr in the presence of 10 mg/ml protamine sulfate. Puromycin was added to cell culture media at a concentration of 2 mg/ml for selection. The sequences of shRNAs are as follows:
The ARF (mousespecific) hairpin was described previously (Apicelli et al., 2008) .
Western Blotting
Cell pellets were lysed and sonicated in EBC lysis buffer (50 mM Tris-Cl [pH 7.4], 120 mM NaCl, 0.5% NP-40, 1 mM EDTA) containing HALT Protease and Phosphatase Inhibitor cocktail (Thermo Scientific) and 1 mM phenylmethanesulfonylfluoride. A total of 30 mg of protein were separated on SDS-polyacrylamide gels. Proteins were transferred to PVDF (Millipore) and probed with antibodies. ARF (mouse), actin, p53 (human), g-tubulin, H-Ras, ISG15 (human), and STAT1 were all purchased from Santa Cruz Biotechnologies. p53
, phospho-STAT3 Tyr705 , and STAT3 were purchased from Cell Signaling. ARF (human) and GAPDH were purchased from Bethyl Laboratories, and MDM2 was from Millipore. The mouse ISG15 antibody was a gift from Dr. Deborah Lenschow. Secondary horseradish peroxidase-conjugated antibodies (Jackson Immunoresearch) were used, and ECL plus was used to visualize the bands (GE Healthcare).
Proliferation, BrdU, and Foci Assays For proliferation assays, 5-10 3 10 4 cells were plated in six-well plates. Cells were lifted and counted using a hemocytometer at the indicated number of days postplating. For BrdU assays, 1 3 10 4 cells were plated on glass coverslips and incubated overnight. A total of 10 mM BrdU-containing media was added to the cells for 4-6 hr. Cells were fixed with 10% formalin/methanol, and BrdU staining was performed using a BrdU antibody (GE Healthcare) according to the manufacturer's instructions. For foci assays, 3 3 10 3 cells
were plated in 10 cm dishes and cells were incubated for 10 days. Cells were fixed with 100% methanol and stained with Giemsa (Sigma Aldrich).
Soft Agar Assay
Cells were lifted and suspended in DMEM containing a final concentration of 0.4% noble agar. A total of 1.5 3 10 4 cells were layered in triplicate onto 0.6% noble-agar/media bottom layer in 60 mm plates. Plates were incubated for 20 days, feeding with media/0.4% agar mix every 6 days. Macroscopic colonies were visualized by staining with 0.005% crystal violet solution and colonies R0.5 mm were manually counted.
Tumorigenesis Assay A total of 1.5 3 10 6 dp53R-shSCR or dp53R-shARF MEFs were resuspended in PBS and injected into the flanks of female homozygous athymic nude mice (Foxn1 nu /Foxn1 nu ) obtained from Jackson Laboratory. Five mice per condition were used. Tumor size was monitored over the course of 20 days using calipers to measure in two dimensions. Tumor volume was calculated using the formula: volume = [(height) 2 3 length]/2, in which height equals the smallest of the two measurements.
Microarray Analysis
RNA was isolated from dp53R-shSCR or dp53R-shARF MEFs using a Nucleospin RNA II Kit (Clonetech). RNA samples from three independent experiments were submitted to the Genome Technology Access Center at Washington University School of Medicine for microarray analysis. Affymetrix Gene 1.0ST arrays were used, and data were processed in Affymetrix Expression Console (Affymetrix version) using the RMA (robust multichip average) algorithm. Differential expression analysis was performed using significant analysis of microarrays, and a list of differentially expressed genes exhibiting fold changes greater than 2 was generated. Pathway analysis was performed using MetaCore software (Thomson Reuters).
Quantitative Real-Time PCR qRT-PCR was performed as previously described (Miceli et al., 2012) . Fold change was measured using the DDC T method. Primer sequences used for amplification were as follows: 
IFN-b ELISA
Cell culture supernatants were concentrated using Vivaspin columns (GE Healthcare) according to the manufacturer's instructions. Mouse IFN-b levels were measured using the Verikine Mouse Interferon Beta ELISA Kit (PBL Interferon Source) according to the manufacturer's instructions.
Immunohistochemistry
Annotated breast cancer tissue arrays were obtained from US Biomax (Cat#BR1503a). Staining was performed using the Dako EnVision+ System-HRP (DAB) according to the manufacturer's instructions. Rabbit antip14ARF (Bethyl) and mouse anti-iSG15 (Santa Cruz) were used at a 1:200 dilution. Quantification was performed by two separate individuals by blindly scoring staining intensity on a 0-3 scale, with 0 being no staining and 3 being strong widespread staining. A score of 0-1 was considered ''low/no'' staining, and a score of 2-3 was considered ''high.'' Statistical Analysis. Data are presented as means ± SD. Statistical differences between groups were determined with p values obtained using two-sided, unpaired Student's t test. All data points represent n = 3. All images presented as ''representative'' were completed a minimum of three times.
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